Biopharma companies lost significant stock market value in December and entered the New Year with a stranglehold on SEC filings due to the longest-ever government shutdown, so it is no wonder it took five weeks for the industry to complete its first IPO of 2019. Read More
Although Wall Street hammered shares of Solid Biosciences Inc. (NASDAQ:SLDB) down to $15.15, or 67.8 percent, to close them Thursday at $7.19, company officials told investors of a thesis based on preclinical work that could lead to better results with SGT-001 microdystrophin gene transfer for Duchenne muscular dystrophy (DMD) Read More
PERTH, Australia – As pharma companies face global pricing pressures, value-based pricing mechanisms and health technology assessments more often than not determine which drugs get reimbursed and, ultimately, make it to the patient. Read More
The U.S. Court of Appeals for the Federal Circuit Thursday dismissed Momenta Pharmaceuticals Inc.'s appeal of a Patent Trial and Appeal Board (PTAB) decision sustaining patent claims protecting Bristol-Myers Squibb Co.'s (BMS) arthritis drug, Orencia. Read More
A brain implant that translates thought into speech for those without that capacity sounds like science fiction. But now New York-based Columbia University researchers have become the first to generate sounds that are intelligible to human listeners via interpretation of brain signals. They made this promising advance by applying deep learning to neural data derived from five epilepsy patients during monitoring to identify a portion of their brain for surgical removal to quell severe tremors. Read More
NED Biosystems Inc., a Cambridge, Mass.-based venture developing a seven-agent combination therapy for cancer, has secured a U.S. patent for the treatment, called NED-170. The oral regimen, which comes in a daily seven-pill pack, targets both angiogenic and immune response pathways for the potential treatment of several types of cancers. If successful, it could potentially help not only extend lives, but also drive down the costs of cancer care in certain cases. Read More
Biolinerx Ltd., of Tel Aviv, Israel, said it closed its public offering of 28 million American depositary shares priced at 75 cents apiece for gross proceeds of $15.4 million. Net proceeds will be used for general corporate purposes. Oppenheimer & Co. Inc. acted as sole book-running manager, while Maxim Group LLC acted as co-manager. Read More
Amag Pharmaceuticals Inc., of Waltham, Mass., reported that its revenues from continuing operations for 2018 totaled $474 million, compared with $495.8 million in 2017. Read More
In a split opinion in Athena Diagnostics Inc. v. Mayo Collaborative Services LLC, the U.S. Court of Appeals for the Federal Circuit this week upheld a lower court ruling invalidating patent claims covering methods for diagnosing neurological disorders, such as myasthenia gravis, by detecting antibodies to muscle-specific tyrosine kinase. Read More
Soligenix Inc., of Princeton, said an article published in the European Journal of Pharmaceutics and Biopharmaceutics demonstrates successful thermostabilization of an Ebola subunit vaccine candidate. Read More
